CareCloud, Inc. (CCLD) Q3 2024 Earnings Call Transcript Summary
CareCloud, Inc. (CCLD) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the CareCloud, Inc. (CCLD) Q3 2024 Earnings Call Transcript:
以下是CareCloud, Inc. (CCLD) 2024年第三季度業績電話會議摘要:
Financial Performance:
財務表現:
CareCloud reported adjusted EBITDA of $6.8 million for Q3 2024, a 111% increase over the previous year, and a 328% increase in year-to-date free cash flow, reaching $10.3 million.
Revenue for Q3 2024 was $28.5 million, slightly down from $29.3 million in Q3 2023 due to fluctuations in non-recurring revenue from the medSR division.
Fully paid off a $10 million credit line and on track to resume monthly dividend payments on Series A and Series B preferred shares in March 2025.
CareCloud報告2024年第三季度調整後的EBITDA爲680萬美元,較去年同期增長111%,自由現金流年度增長328%,達到1030萬美元。
2024年第三季度營業收入爲2850萬美元,略低於2023年第三季度的2930萬美元,因medSR部門非經常性營收波動。
全額償還了1000萬美元的信用額度,並計劃於2025年3月恢復對A類和B類優先股的月度股利支付。
Business Progress:
業務進展:
Advanced the development and integration of CareCloud CirrusAI, enhancing clinical efficiency and patient outcomes.
Focus on generating free cash flow saw the full repayment of bank debt and a strong increase in net GAAP income from a net loss in the previous year to $3.1 million in Q3 2024.
推進了CareCloud CirrusAI的開發與整合,提升臨床效率和患者結果。
專注於產生自由現金流,全額償還了銀行債務,並將淨GAAP收入從上一年的淨虧損增至2024年第三季度310萬美元。
Opportunities:
機會:
Utilizing CareCloud CirrusAI across their EHR systems to expand service capability and reach, with emerging ventures into AI-powered solutions showing promising growth potential.
Identified revenue opportunities with life sciences partners, leveraging extensive data assets for multiple uses including risk assessments and research by these partners.
利用CareCloud CirrusAI跨越他們的EHR系統以擴大服務能力和覆蓋範圍,同時涉足人工智能解決方案領域,展示出有希望的增長潛力。
通過與生命科學合作伙伴識別出營收機會,利用豐富的數據資產進行多種用途,包括這些合作伙伴進行的風險評估和研究。
Risks:
風險:
The fluctuating revenues of the medSR division pose a challenge in predicting consistent future revenues in professional services, especially given past issues with service restrictions by a major client like APIC.
medSR部門營收波動帶來了一個挑戰,即在專業服務領域中對未來營收的一貫預測,尤其是考慮到此部門過去與APIC等主要客戶的服務限制問題。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。